CSuitePharma’s Post

New FDA drug approvals hit a record high in 2023, with specialty drugs now making up 54% of claims spending. Our latest whitepaper “Bridging the Value Gap” explores how #payers can benefit from closer alignment on medical and drug benefits. Download now! https://ow.ly/rbbx50SZIU5 #Healthcare #SpecialtyDrugs #HealthPolicy

New FDA drug approvals hit a record high in 2023, with specialty drugs now making up 54% of claims spending. Our latest whitepaper “Bridging the Value Gap” explores how #payers can benefit from closer alignment on medical and drug benefits. Download now! https://ow.ly/qKYg50SWS8T #Healthcare #SpecialtyDrugs #HealthPolicy

New FDA drug approvals hit a record high in 2023, with specialty drugs now making up 54% of claims spending. Our latest whitepaper “Bridging the Value Gap” explores how #payers can benefit from closer alignment on medical and drug benefits. Download now! https://ow.ly/XCjv50SWSIJ #Healthcare #SpecialtyDrugs #HealthPolicy

For the first time, the U.S. government has the power to directly negotiate with drug companies the prices of medicines prescribed to Medicare Part D patients. The negotiations kick off today, as the Biden administration sends to manufacturers its initial offers for the first 10 drugs selected for negotiation. Months of talks will follow, all while the pharma industry is waging a legal challenge to the portion of the 2022 Inflation Reduction Act that authorizes the negotiations. The industry opposes the process and hopes to block the reduced prices from taking effect. What do you think of the new Medicare drug-price negotiations? #drugprices #inflationreductionact

Novel (new) Drug Approvals in 2023- FDA. Exciting News! 🌟 In 2023, the FDA has approved novel drugs that are set to revolutionize patient care and significantly improve lives. 🚀 These groundbreaking advancements mark a major stride in healthcare innovation. 🌐 Stay informed about the latest Novel Drug Approvals in 2023 and their impact on patient well-being. The future of healthcare is here! #FDAApprovals #HealthcareInnovation #PatientCare #MedicalAdvancements #InnovativeMedicine #NewDrugApprovals #HealthTech #MedicalBreakthroughs #PatientWellbeing #HealthcareRevolution #2023MedicalAdvances Let's celebrate progress and the potential these new drugs hold for a healthier, brighter future! 🎉💊 #MedicalProgress #FutureOfHealthcare #DrugDevelopment #MedicineMilestones #PharmaInnovation #HealthcareLeadership #MedicalResearch #HealthcareTransformation #InnovateForGood

🌟 Important Update 🌟 Yesterday, the U.S. Senate passed a critical provision of the bipartisan Affordable Prescriptions for Patients Act, a victory for increased competition and lower pharmaceutical prices. Authored by Senators John Cornyn (R-TX) and Richard Blumenthal (D-CT), this legislation targets "patent thickets" that hinder competition and inflate costs. The Public Sector HealthCare Roundtable has long championed these reforms and applauds the bipartisan effort to pass this key provision. This is a significant step toward ending anti-competitive practices and passing drug savings along to public sector purchasers. Visit our website to learn more https://lnkd.in/ed_Nsr9T #Healthcare #AffordablePrescriptions #BipartisanSupport #PublicSector

Sometimes two things that seem opposing can be true. The Hill has an article about how pharmaceutical CEOs are hinting that the negotiated prices may not be so bad. And then you have this quote, “There also is just the reality that they have been saying that the sky has been falling. And if CMS comes out with a completely reasonable price, that does a lot to their credibility" (AARP.) Let's pause and chew on that. Yes, this round of prices might fit within what CEOs and investors anticipated (more or less). Many of these products are already subject to intense negotiations. But let's not let that fool us into believing there's no harm done, now or later. This was never about a single round of "pseudo-negotiation." The ceaseless clock of negotiations chips away at innovation, particularly on follow-on indications that get caught in the small molecule clock. That's no idle speculation. https://lnkd.in/eBtFD28w

On October 10, Teva Pharmaceuticals agreed to pay $450 million to resolve allegations of violating the Anti-Kickback Statute (AKS) and the False Claims Act (FCA). The settlement addresses two major kickback schemes involving Medicare patient copays and price-fixing in generic drugs. Key Highlights: - Teva allegedly paid Medicare patients' copays for its multiple sclerosis drug, Copaxone, while increasing the drug’s price. - The company conspired with third parties, including foundations and a pharmacy, to cover these copays, violating AKS. - Teva also admitted to price-fixing for generic drugs, including pravastatin, and paid a criminal penalty of $225 million for related charges. - The combined settlement of $450 million includes civil penalties related to both kickback schemes. This settlement marks the largest in a series of actions by the Department of Justice against pharmaceutical companies for unlawful patient copay payments. For more updates on healthcare compliance and regulatory enforcement, unlock cutting-edge legal intelligence with our subscription free platform—join us today! Visit https://lnkd.in/gZmkUPim to learn more. #Healthcare #Pharmaceuticals #Compliance #FalseClaimsAct #AntiKickback #PriceFixing #Medicare #GRI #Teva #Regulation #LegalUpdates

In a new piece, our President and CEO Julio Fuentes, discusses the importance of preserving flexibility for #Florida employers to create affordable, high-quality prescription drug coverage. Instead of eliminating this flexibility, #policymakers at both the federal and state levels should focus on addressing the root cause of high prescription drug prices. Let's build on the foundation set in SB 1550 for holding big drug companies accountable. Read the article here: https://lnkd.in/gD8v-Pyy

Hatch-Waxman Amendments, Drug Shortages Lead FDA’s 2025 Legislative Agenda: The FDA’s legislative wish list for FY 2025 includes proposals to protect drug supply resiliency, amend the Hatch-Waxman Act, and exercise greater control over recalls. #fda #financial #lifesciences